B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset pompe disease

Journal of Pediatrics

Volumn 163, Issue 3, 2013, Pages

  Elder, Melissa E ^a   Nayak, Sushrusha ^b   Collins, Shelley W ^a   Lawson, Lee Ann ^b   Kelley, Jeffry S ^b   Herzog, Roland W ^a   Modica, Renee F ^a   Lew, Judy ^a   Lawrence, Robert M ^a   Byrne, Barry J ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Ab; Acid alpha glucosidase; Antibody; CRIM; Cross reactive immunologic material; Enzyme replacement therapy; ERT; GAA; Intravenous; Intravenous immunoglobulin; IV; IVIG; Left ventricular mass index; LVMI

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CD19 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CREATINE KINASE; CREATINE KINASE MB; GAMMA GLUTAMYLTRANSFERASE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RAPAMYCIN; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; RITUXIMAB;

ANTIBODY RESPONSE; ARTICLE; ASSISTED VENTILATION; AUDIOMETRY; CALORIC INTAKE; CHILD; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; FEMALE; FLOW CYTOMETRY; GLYCOGEN STORAGE DISEASE TYPE 2; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFANT DISEASE; INFUSION RATE; LOADING DRUG DOSE; LUNG FUNCTION TEST; MALE; MUSCLE STRENGTH; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; ONSET AGE; OUTCOME ASSESSMENT; PASSIVE IMMUNIZATION; PERCEPTION DEAFNESS; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYSOMNOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKIN FIBROBLAST; STOMACH TUBE; STOP CODON; T LYMPHOCYTE SUBPOPULATION; THROMBOCYTE; TRACHEOSTOMY; TREATMENT DURATION;

EID: 84882887346     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2013.03.002     Document Type: Article

References (23)

1. B.J. Byrne, P.S. Kishnani, L.E. Case, L. Merlini, W. Muller-Felber, and S. Prasad Pompe disease: design, methodology, and early findings from the Pompe Registry Mol Genet Metab 103 2011 1 11
2. D.S. Bali, J.L. Goldstein, S. Banugaria, J. Dai, J. Mackey, and C. Rehder Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience Am J Med Genet C Semin Med Genet 160 2012 40 49
3. J.M. de Vries, N.A. van der Beek, M.A. Kroos, L. Ozkan, P.A. van Doorn, and S.M. Richards High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa Mol Genet Metab 101 2010 338 345
4. P.S. Kishnani, P.C. Goldenberg, S.L. DeArmey, J. Heller, D. Benjamin, and S. Young Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants Mol Genet Metab 99 2010 26 33
5. Y.H. Messinger, N.J. Mendelsohn, W Rhead, D Dimmock, E Hershkovitz, and M. Champion Successful immune tolerance induction to enzyme replacement therapy in CRIM-negativeinfantile Pompe disease Genet Med 14 2012 135 142
6. S.G. Banugaria, T.T. Patel, J. Mackey, S. Das, A. Amalfitano, and A.S. Rosenberg Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells Mol Genet Metab 105 2012 677 680
7. M. Nicolino, B. Byrne, J.E. Wraith, N. Leslie, H. Mandel, and D.R. Freyer Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease Genet Med 11 2009 210 219
8. B.J. Byrne, D.J. Falk, C.A. Pacak, S. Nayak, R.W. Herzog, and M.E. Elder Pompe disease gene therapy Hum Mol Genet 20 2011 R61 R68
9. A. Amalfitano, A.R. Bengur, R.P. Morse, J.M. Majure, L.E. Case, and D.L. Veerling Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial Genet Med 3 2001 132 138
10. M. Rohrbach, A. Klein, A. Kohli-Wiesner, D. Veraguth, I. Scheer, and C. Balmer CRIM-negative infantile Pompe disease: 42-month treatment outcome J Inherit Metab Dis 33 2010 751 757
11. N.J. Mendelsohn, Y.H. Messinger, A.S. Rosenberg, and P.S. Kishnani Elimination of antibodies to recombinant enzyme in Pompe's disease N Engl J Med 360 2009 194 195
12. S. Banugaria, S. Nampoothiri, J. Feldman, J. Kabori, J. MsGann, and D. Koeberl Bortezomib: a solution to the challange of antibodies in diseases treated with therapeutic proteins? Mol Genet Metab 102 2011 S6 S7
13. + regulatory T cells Blood 105 2005 4743 4748
14. O. Bestard, L. Cassis, J.M. Cruzado, J Torras, M Franquesa, and S. Gil-Vernet Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation Transplant Int 24 2011 451 460
15. S. Nayak, O. Cao, B.E. Hoffman, M. Cooper, S. Zhou, and M.A. Atkinson Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells J Thromb Haemost 7 2009 1523 1532
16. B. Moghimi, B.K. Sack, S. Nayak, D.M. Markusic, C.S. Mah, and R.W. Herzog Induction of tolerance to factor VIII by transient co-administrationwith rapamycin J Thromb Haemost 9 2011 1524 1533
17. J. Levitsky, J.M. Mathew, M. Abecassis, A. Tambur, J. Leventhal, and D. Chandrasekaran Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients Hepatology 57 2012 239 248
18. K.M. Ashe, K.M. Taylor, Q. Chu, E. Meyers, A. Ellis, and V. Jingozyan Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease Mol Genet Metab 100 2010 309 315
19. P.S. Kishnani, M. Nicolino, T. Voit, R.C. Rogers, A.C. Tsai, and J. Waterson Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease J Pediatr 149 2006 89 97
20. P.S. Kishnani, D. Corzo, M. Nicolino, B. Byrne, H. Mandel, and W.L. Hwu Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease Neurology 68 2007 99 109
21. L.R. DeRuisseau, D.D. Fuller, K. Qiu, K.C. DeRuisseau, W.H. Donnelly Jr., and C. Mah Neural deficits contribute to respiratory insufficiency in Pompe disease Proc Natl Acad Sci USA 106 2009 9419 9424
22. K.Z. Lee, K. Qiu, M.S. Sandhu, M.K. Elmallah, D.J. Falk, and M.A. Lane Hypoglossal neuropathology and respiratory activity in3we pompe mice Front Physiol 2 2011 31
23. K. Qiu, D.J. Falk, P.J. Reier, B.J. Byrne, and D.D. Fuller Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice Mol Ther 20 2012 21 27